Percutaneous Transcatheter Genicular Embolization in Osteoarthritis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-80
SponsorMasarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.

About this trial

This clinical study investigates a minimally invasive treatment called percutaneous transcatheter embolization of knee arteries for patients with chronic knee pain caused by advanced knee osteoarthritis or persistent pain after total knee replacement. Osteoarthritis of the knee is a common degenerative condition that can lead to long-term pain, reduced mobility, and decreased quality of life, and some patients do not achieve sufficient relief with standard treatments.

The study is based on the hypothesis that targeted embolization of small arteries supplying the inflamed tissues of the knee can safely reduce abnormal blood flow associated with inflammation, leading to pain relief and improved knee function. During the procedure, a thin catheter is guided through the blood vessels to the affected area of the knee, where a temporary embolic agent is administered to reduce pathological blood supply.

The aim of the study is to evaluate the safety and effectiveness of this procedure by assessing changes in pain intensity, knee function, and quality of life over a follow-up period of up to 24 months. The results of this study may help determine whether this minimally invasive approach can offer a new treatment option for patients who have limited alternatives for managing chronic knee pain

Eligibility criteria

Qualifiers

Adults aged 40 to 80 years

Clinical symptoms consistent with chronic knee pain

Radiographically confirmed knee osteoarthritis of Kellgren-Lawrence grade II-IV or persistent knee pain following total knee arthroplasty

Insufficient pain relief after standard conservative treatment (e.g., pharmacological therapy, physical therapy, or injections)

Disqualifiers

Active local or systemic infection

Known coagulation disorders or ongoing anticoagulation that cannot be safely interrupted

Significant peripheral arterial disease affecting the lower limbs

Known allergy or contraindication to iodinated contrast agents

Trial design

Treatments tested in this trial

  • genicular artery embolisation

Treatment groups

20 Participants
are divided into 1 treatment group